Caribou Biosciences IPO
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company developing programmed allogeneic cell therapies. The company focuses on off-the-shelf CAR-T and CAR-NK cell therapies for treating hematologic malignancies and solid tumors. Investors are interested in its differentiated CRISPR platform and potential to address limitations of current cell therapies.
What We Know
Caribou Biosciences completed its initial public offering in July 2021, trading on NASDAQ under the ticker symbol CRBU. The company raised approximately $200 million in its IPO, pricing shares at $16 each, which was at the high end of its expected range of $14-16. Since going public, the stock has experienced significant volatility typical of biotech companies, with performance tied to clinical trial updates and regulatory milestones. The company continues to advance its pipeline of allogeneic cell therapies through various stages of clinical development.
Frequently Asked Questions
Has Caribou Biosciences had an IPO?
Yes, Caribou Biosciences completed its IPO in July 2021. The company has been publicly traded on NASDAQ under the ticker CRBU since then.
When is the Caribou Biosciences IPO date?
Caribou Biosciences already completed its IPO on July 23, 2021. The company is currently trading as a public company on NASDAQ.
How can I buy Caribou Biosciences stock?
You can buy Caribou Biosciences stock through any brokerage account since it trades publicly on NASDAQ under the ticker CRBU. The stock is available during regular market hours and can be purchased like any other publicly traded security.
Don't Miss the Next Big IPO
Get notified when the next major company files for an IPO. Daily alerts delivered to your inbox.
Get IPO Alerts